CYP19A1 and cancer: In large chemoprevention studies of cancer-free postmenopausal women at increased risk for breast cancer as assigned by family history (but not genotyped for BRCA P/LPVs), both raloxifene and aromatase inhibitors (AIs) were associated with a lower risk of breast cancer [22,23,24].